Document Detail

Crush stenting in treating coronary bifurcate lesions: paclitaxel eluting stents versus sirolimus eluting stents.
MedLine Citation:
PMID:  18364140     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Because no data regarding the comparison of crush stenting with paclitaxel (PES) or sirolimus eluting stents (SES) for coronary bifurcate lesions have been reported, we compared the clinical outcomes of these two types of stents. METHODS: Two hundred and thirty patients with 242 bifurcate lesions were enrolled in a prospective, nonrandomized trial. Primary endpoints included myocardial infarction, cardiac death and target vessel revascularization at 8 months. RESULTS: All patients were followed up clinically and 82% angiographically at 8 months. Final kissing balloon inflation was performed in 72% in the PES and 75% in the SES groups (P>0.05). Compared to the SES group, PES group had a higher late loss and incidence of restenosis (P=0.04) in the prebifurcation vessel segment. The postbifurcation vessel segment in the PES group had a greater late loss ((0.7+/-0.6) mm vs (0.3+/-0.4) mm, P<0.001) and higher restenosis in the side branch (25.5% vs 15.6%, P=0.04) when compared to the SES group. There was significant difference of insegment restenosis in the entire main vessel between PES and SES groups (P=0.004). Target lesion revascularization was more frequently seen in the PES group as compared to the SES group (P=0.01). There was significant difference in the accumulative MACE between these two groups (P=0.01). The survival rate free from target lesion revascularization was significantly higher in the SES group when compared to the PES group (P<0.001). CONCLUSION: SES is superior to PES in reducing restenosis and target lesion revascularization by 8-month follow-up after crush stenting for bifurcate lesions.
Shao-liang Chen; Jun-jie Zhang; Fei Ye; Yun-dai Chen; Zhong-sheng Zhu; Song Lin; Nai-liang Tian; Zhi-zhong Liu; Wei-yi Fang; Xue-wen Sun; Da-yi Hu; Tak W Kwan
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Chinese medical journal     Volume:  121     ISSN:  0366-6999     ISO Abbreviation:  Chin. Med. J.     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-03-26     Completed Date:  2008-06-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513795     Medline TA:  Chin Med J (Engl)     Country:  China    
Other Details:
Languages:  eng     Pagination:  528-33     Citation Subset:  IM    
Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary / methods*
Coronary Angiography
Coronary Artery Disease / therapy*
Drug-Eluting Stents*
Follow-Up Studies
Middle Aged
Paclitaxel / administration & dosage*
Prospective Studies
Sirolimus / administration & dosage*
Reg. No./Substance:
33069-62-4/Paclitaxel; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via t...
Next Document:  Comparison of coronary plaque composition among patients with acute coronary syndrome and stable cor...